Early trial drug for advanced solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic solid cancer that has progressed or you cannot tolerate/receive standard treatments.
- You can join one of the study parts based on your prior biopsy (for example, NSCLC with EGFR mutations in one group).
- You have at least one measurable tumor spot that was seen on a recent CT or MRI.
- Your body function level is good (ECOG 0–1) and you have an expected survival longer than 12 weeks.
- Your brain/spinal fluid is stable: no active or uncontrolled brain metastases or carcinomatous meningitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
This early-phase study tests CBP-1018 in people with advanced solid tumors, such as prostate, kidney, or certain lung cancers. It aims to see how the drug works and whether it’s safe enough to continue studying.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.